Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
President and Chief Executive Officer Tandem Diabetes Care, Inc.
Mr. Blickenstaff has served as the president and chief executive officer of Tandem Diabetes Care, Inc., a privately held medical device company, since 2007. Prior to joining Tandem, Mr. Blickenstaff served as president, chief executive officer and co-founder of Biosite Incorporated. In addition, he has held various positions in finance, operations, research management, sales management, strategic planning and marketing with Baxter Travenol, National Health Laboratories and Hybritech Incorporated. He also serves as a director of several privately-held medical products companies. Mr. Blickenstaff received a B.A. from Loyola Marymount College and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.
Mr. Adams has been the President and Chief Executive Officer of Protein Sciences Corporation, a biopharmaceutical service company since 1995. He has founded a number of life sciences companies, among them Biogen, where he served as the first Chief Executive Officer. Mr. Adams holds a B.A. degree in Chemistry from Cornell University and a J.D. magna cum laude from New York University School of Law.
Dr. Bailey has been managing partner of Palantir Group, Inc., a biotechnology merchant bank, since 2007. He was managing director of investment banking at MDB Capital Group from 2004 to 2007, and a life sciences analyst at Participating Capital from 1995 to 2004. Dr. Bailey holds an M.D. degree from the University of Western Ontario.
President and Chief Executive Officer, Director Medivation, Inc.
Dr. Hung served as president, chief executive office and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. ProDuct Health, Inc was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College.
Former Company Group Chairman DePuy Orthopedics, Inc. Former President Centocor, Inc.
Mr. Vernon has 23 years experience serving in senior executive positions at various Johnson & Johnson companies, including Company Group Chairman of DePuy Orthopedics, Inc. (2004-2005), President of Centocor, Inc. (2001-2004), President of McNeil Consumer Healthcare (1999-2001), and President Worldwide of the Johnson & Johnson Merck Joint Venture. Mr. Vernon received a B.A. from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management.
= Chair of the Board = Chair = Member = Independent Director
Stock transaction information provided by EDGAR Online. Medivation, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
= Chair of the Board
= Chair
= Member
= Independent Director
